Drug delivery across the blood-brain barrier (BBB) limits the efficacy of pharmacological therapy of brain tumors. For instance the anticancer drug doxorubicin, that is effective in vitro, has a poor efficacy in vivo because it is extruded through several efflux pumps like P-glycoprotein (Pgp), multidrug resistance-related proteins (MRPs) and breast cancer resistance protein (BCRP), present at high levels on BBB cells. 1 We have previously observed that the anticholesterolemic drug statins reduce the activity of the efflux pumps in
